NCT00297089

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 165 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the efficacy of ABT-751 when administered in combination with standard pemetrexed in subjects with advanced or metastatic NSCLC. The Phase 1 portion of the study is complete and the study is currently enrolling subjects in Phase 2.

Conditions

• Lung Cancer
• NSCLC
• Non-Small-Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	ABT-751	200 mg ABT-751 daily for 14 days every 21 days
DRUG	pemetrexed	Standard pemetrexed every 21 days
DRUG	placebo	Placebo daily for 14 days every 21 days

Timeline

• Start date: 2006-11-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2006-02-28
• Last updated: 2013-01-31

Locations

48 sites across 6 countries: United States, Czechia, Greece, Hungary, Netherlands, Slovakia